Leerink Partnrs Has Negative Outlook of CRBU FY2025 Earnings

Caribou Biosciences, Inc. (NASDAQ:CRBUFree Report) – Research analysts at Leerink Partnrs decreased their FY2025 earnings per share estimates for shares of Caribou Biosciences in a research report issued on Wednesday, January 22nd. Leerink Partnrs analyst M. Foroohar now expects that the company will earn ($1.77) per share for the year, down from their previous estimate of ($1.64). The consensus estimate for Caribou Biosciences’ current full-year earnings is ($1.64) per share. Leerink Partnrs also issued estimates for Caribou Biosciences’ FY2026 earnings at ($1.84) EPS, FY2027 earnings at ($1.83) EPS, FY2028 earnings at ($0.54) EPS and FY2029 earnings at $0.28 EPS.

Several other equities analysts have also weighed in on CRBU. Citigroup cut their target price on Caribou Biosciences from $30.00 to $6.00 and set a “buy” rating on the stock in a research note on Tuesday, November 26th. HC Wainwright reissued a “buy” rating and set a $9.00 price objective on shares of Caribou Biosciences in a research note on Friday, November 15th. Finally, Bank of America lowered their target price on shares of Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and an average target price of $10.33.

View Our Latest Stock Report on Caribou Biosciences

Caribou Biosciences Stock Performance

Shares of Caribou Biosciences stock opened at $1.51 on Friday. Caribou Biosciences has a 52 week low of $1.47 and a 52 week high of $8.33. The stock has a market capitalization of $136.73 million, a price-to-earnings ratio of -0.92 and a beta of 2.34. The firm has a fifty day moving average of $1.83 and a two-hundred day moving average of $2.00.

Caribou Biosciences (NASDAQ:CRBUGet Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.38) EPS for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.06. The firm had revenue of $2.02 million during the quarter, compared to analyst estimates of $3.37 million. Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.81%.

Hedge Funds Weigh In On Caribou Biosciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Erste Asset Management GmbH bought a new stake in shares of Caribou Biosciences in the third quarter valued at about $28,000. AQR Capital Management LLC bought a new stake in Caribou Biosciences in the 2nd quarter valued at approximately $30,000. China Universal Asset Management Co. Ltd. boosted its position in Caribou Biosciences by 63.8% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 17,380 shares of the company’s stock worth $34,000 after acquiring an additional 6,768 shares during the last quarter. Intech Investment Management LLC bought a new position in shares of Caribou Biosciences during the 3rd quarter worth approximately $43,000. Finally, Point72 DIFC Ltd raised its holdings in shares of Caribou Biosciences by 389.4% in the second quarter. Point72 DIFC Ltd now owns 30,157 shares of the company’s stock valued at $49,000 after purchasing an additional 23,995 shares during the last quarter. 77.51% of the stock is owned by institutional investors and hedge funds.

Caribou Biosciences Company Profile

(Get Free Report)

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.

Further Reading

Earnings History and Estimates for Caribou Biosciences (NASDAQ:CRBU)

Receive News & Ratings for Caribou Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caribou Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.